Roivant Sciences (ROIV) Assets Average (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Assets Average came in at $5.5 billion in Q1 2026, down 2.63% YoY from $5.6 billion in Q1 2025, and up 6.28% on a QoQ basis from $5.1 billion in Q4 2025.
Roivant Sciences (ROIV) Assets Average (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Assets Average data on file, last reported at $5.5 billion in Q1 2026.
- Quarterly Assets Average fell 2.63% year-over-year to $5.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 billion (down 2.63% YoY) and the FY2026 annual result came in at $5.5 billion, down 2.63% from the prior year.
- Assets Average advanced to $5.5 billion in Q1 2026, from $5.1 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $7.3 billion in Q1 2024 to a low of $2.1 billion in Q3 2023.
- A 5-year average of $4.4 billion and a median of $5.0 billion in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average dropped 25.14% — and 2024, when it soared 216.49%.
- Tracing ROIV's Assets Average over 5 years: stood at $2.2 billion in 2022, then surged by 112.25% to $4.7 billion in 2023, then gained by 27.94% to $6.0 billion in 2024, then fell by 14.26% to $5.1 billion in 2025, then grew by 6.28% to $5.5 billion in 2026.
- The last three Assets Average figures came in at $5.5 billion (Q1 2026), $5.1 billion (Q4 2025), and $5.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.51 Bn |
| Mar 31, 2026 | 5.47 Bn |
| Dec 31, 2025 | 5.14 Bn |
| Sep 30, 2025 | 5.05 Bn |
| Jun 30, 2025 | 5.23 Bn |
| Mar 31, 2025 | 5.61 Bn |
| Dec 31, 2024 | 6.00 Bn |
| Sep 30, 2024 | 6.35 Bn |
| Jun 30, 2024 | 6.86 Bn |
| Mar 31, 2024 | 7.27 Bn |
| Dec 31, 2023 | 4.69 Bn |
| Sep 30, 2023 | 2.10 Bn |
| Jun 30, 2023 | 2.26 Bn |
| Mar 31, 2023 | 2.30 Bn |
| Dec 31, 2022 | 2.21 Bn |
| Sep 30, 2022 | 2.41 Bn |
| Jun 30, 2022 | 2.59 Bn |
| Mar 31, 2022 | 2.69 Bn |
| Dec 31, 2021 | 2.95 Bn |
| Sep 30, 2021 | 2.78 Bn |